Department of Endocrinology, Metabolism and Cancer, Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris, France.
Gut. 2011 Feb;60(2):166-76. doi: 10.1136/gut.2009.204719.
The activation of β-catenin signalling is a key step in intestinal tumorigenesis. Interplay between the β-catenin and Notch pathways during tumorigenesis has been reported, but the mechanisms involved and the role of Notch remain unclear.
Notch status was analysed by studying expression of the Notch effector Hes1 and Notch ligands/receptors in human colorectal cancer (CRC) and mouse models of Apc mutation. A genetic approach was used, deleting the Apc and RBP-J or Atoh1 genes in murine intestine. CRC cell lines were used to analyse the control of Hes1 and Atoh1 by β-catenin signalling.
Notch signalling was found to be activated downstream from β-catenin. It was rapidly induced and maintained throughout tumorigenesis. Hes1 induction was mediated by β-catenin and resulted from both the induction of the Notch ligand/receptor and Notch-independent control of the Hes1 promoter by β-catenin. Surprisingly, the strong phenotype of unrestricted proliferation and impaired differentiation induced by acute Apc deletion in the intestine was not rescued by conditional Notch inactivation. Hyperactivation of β-catenin signalling overrode the forced differention induced by Notch inhibition, through the downregulation of Atoh1, a key secretory determinant factor downstream of Notch. This process involves glycogen synthase kinase 3 β (GSK3β) and proteasome-mediated degradation. The restoration of Atoh1 expression in CRC cell lines displaying β-catenin activation was sufficient to increase goblet cell differentiation, whereas genetic ablation of Atoh1 greatly increased tumour formation in Apc mutant mice.
Notch signalling is a downstream target of β-catenin hyperactivation in intestinal tumorigenesis. However, its inhibition had no tumour suppressor effect in the context of acute β-catenin activation probably due to the downregulation of Atoh1. This finding calls into question the use of γ-secretase inhibitors for the treatment of CRC and suggests that the restoration of Atoh1 expression in CRC should be considered as a therapeutic approach.
β-连环蛋白信号的激活是肠道肿瘤发生的关键步骤。已有报道称,肿瘤发生过程中β-连环蛋白和 Notch 途径之间存在相互作用,但涉及的机制和 Notch 的作用仍不清楚。
通过研究人结直肠癌(CRC)和 Apc 突变小鼠模型中 Notch 效应物 Hes1 和 Notch 配体/受体的表达来分析 Notch 状态。采用基因敲除方法,在小鼠肠道中敲除 Apc 和 RBP-J 或 Atoh1 基因。使用 CRC 细胞系分析β-连环蛋白信号对 Hes1 和 Atoh1 的控制。
发现 Notch 信号转导在β-连环蛋白下游被激活。它在肿瘤发生过程中被迅速诱导并维持。Hes1 的诱导是由β-连环蛋白介导的,这既来自 Notch 配体/受体的诱导,也来自β-连环蛋白对 Hes1 启动子的 Notch 非依赖性控制。令人惊讶的是,急性 Apc 缺失在肠道中引起的不受限制的增殖和分化受损的强烈表型,不能通过条件性 Notch 失活来挽救。β-连环蛋白信号的过度激活通过下调 Notch 下游的关键分泌决定因子 Atoh1,克服了 Notch 抑制诱导的强制分化。这个过程涉及糖原合成酶激酶 3β(GSK3β)和蛋白酶体介导的降解。在显示β-连环蛋白激活的 CRC 细胞系中恢复 Atoh1 的表达足以增加杯状细胞分化,而在 Apc 突变小鼠中遗传敲除 Atoh1 则大大增加了肿瘤形成。
在肠道肿瘤发生中,Notch 信号是β-连环蛋白过度激活的下游靶点。然而,在急性β-连环蛋白激活的情况下,其抑制没有肿瘤抑制作用,可能是由于 Atoh1 的下调。这一发现对使用γ-分泌酶抑制剂治疗 CRC 提出了质疑,并表明应考虑恢复 CRC 中的 Atoh1 表达作为一种治疗方法。